Fibrinolysin

Fibrinolysin

Clinical data
Pregnancy category	C
Routes of administration	ointment for local application, in combination with desoxyribonuclease
ATC code	B01AD05 (WHO)
Legal status
Legal status	Rx only (where available)
Pharmacokinetic data
Bioavailability	virtually none
Metabolism	local inactivation
Elimination half-life	almost completely inactivated after 24 hours
Identifiers
CAS Number	9001-90-5
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Molar mass	~ 13,800 g/mol

WikiDoc Resources for Fibrinolysin
Articles
Most recent articles on Fibrinolysin Most cited articles on Fibrinolysin Review articles on Fibrinolysin Articles on Fibrinolysin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Fibrinolysin Images of Fibrinolysin Photos of Fibrinolysin Podcasts & MP3s on Fibrinolysin Videos on Fibrinolysin
Evidence Based Medicine
Cochrane Collaboration on Fibrinolysin Bandolier on Fibrinolysin TRIP on Fibrinolysin
Clinical Trials
Ongoing Trials on Fibrinolysin at Clinical Trials.gov Trial results on Fibrinolysin Clinical Trials on Fibrinolysin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Fibrinolysin NICE Guidance on Fibrinolysin NHS PRODIGY Guidance FDA on Fibrinolysin CDC on Fibrinolysin
Books
Books on Fibrinolysin
News
Fibrinolysin in the news Be alerted to news on Fibrinolysin News trends on Fibrinolysin
Commentary
Blogs on Fibrinolysin
Definitions
Definitions of Fibrinolysin
Patient Resources / Community
Patient resources on Fibrinolysin Discussion groups on Fibrinolysin Patient Handouts on Fibrinolysin Directions to Hospitals Treating Fibrinolysin Risk calculators and risk factors for Fibrinolysin
Healthcare Provider Resources
Symptoms of Fibrinolysin Causes & Risk Factors for Fibrinolysin Diagnostic studies for Fibrinolysin Treatment of Fibrinolysin
Continuing Medical Education (CME)
CME Programs on Fibrinolysin
International
Fibrinolysin en Espanol Fibrinolysin en Francais
Business
Fibrinolysin in the Marketplace Patents on Fibrinolysin
Experimental / Informatics
List of terms related to Fibrinolysin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Fibrinolysin is an enzyme derived from plasma of bovine origin or extracted from cultures of certain bacteria. It is used locally only and exclusively together with the enzyme desoxyribonuclease (extracted from bovine pancreas). Fibrinolysin and desoxyribonuclease both act as lytic enzymes. The combination is available as ointment containing 1 BU (Biological Unit) fibrinolysin and 666 BUs desoxyribonuclease per gram.

Fibrinolysin attacks and inactivates fibrin molecules occurring in undesirable exudates on the surface of the human body and on human mucosa, e.g., in superficial wounds and burns, while desoxyribonuclease targets and destroys (human) DNA. The combination of the two enzymes has a synergistic effect on necrotic but not on living tissue. According to the manufacturer the ointment provides enhanced wound cleaning and accelerates the healing process.

Both enzymes are marginally resorbed into systemic circulation because of their very high molecular weight and their macromolecular structure.

The activity of both enzymes is almost completely exhausted after 24 hours. Usually, it is necessary to repeat the application (and renew the dressing) every 6 to 8 hours until healing becomes complete.

The ointment is marketed by Pfizer under the brand name Fibrolan® in a variety of countries (e.g. Switzerland). It is currently not approved in the USA.

Where approved, Fibrolan® has been licensed on the basis of claimed good therapeutical experience, but adequate and well controlled studies are still lacking.

In the past, combinations with the antibiotic chloramphenicol were available, but because chloramphenicol in any form of application has led to aplastic anemia and death, these were banned. Additionally, combinations with the antifibrinolytic agent tranexamic acid have been withdrawn from pharma markets.

Indications

Enzymatic wound cleaning to assist healing of minor burns, superficial wounds, ulcus cruris, and superficial hematoma.

Contraindications and Precautions

The ointment should not be used in patients with a known hypersensitivity to any ingredient. It should be used with caution in patients with hypersensitivity to bovine proteins in general and in pregnant women (category C), because no human data is available.

Side-Effects

Infrequently, local reactions such as increased pain or a stitching/burning sensation are noticed. No systemic anticoagulant activity has been seen due to the exclusively local character of treatment.

Interactions

Not known.

External References

• Swiss scientific product information
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6226244&dopt=Abstract (on chemical/biochemical properties)